Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients (Q45117076)

9 December 2017

title

Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients (English)

1 reference

9 December 2017

H T Silva

1

1 reference

9 December 2017

C R Felipe

2

1 reference

9 December 2017

V D Garcia

3

1 reference

9 December 2017

E D Neto

4

1 reference

9 December 2017

M A Filho

5

1 reference

9 December 2017

F L C Contieri

6

1 reference

9 December 2017

D D B M de Carvalho

7

1 reference

9 December 2017

J O M Pestana

8

1 reference

9 December 2017

language of work or name

English

0 references

publication date

30 October 2013

1 reference

American Journal of Transplantation

9 December 2017

published in

1 reference

9 December 2017

volume

13

1 reference

9 December 2017

issue

12

1 reference

9 December 2017

page(s)

3155-3163

1 reference

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

9 December 2017

cites work

1 reference

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?

21 January 2018

1 reference

Sirolimus for calcineurin inhibitors in organ transplantation: contra

21 January 2018

1 reference

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study

21 January 2018

1 reference

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

21 January 2018

1 reference

Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study

21 January 2018

1 reference

Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial

21 January 2018

1 reference

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

21 January 2018

1 reference

Determination of sirolimus blood concentration using high-performance liquid chromatography with ultraviolet detection.

21 January 2018

1 reference

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection

21 January 2018

1 reference

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

21 January 2018

1 reference

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.

21 January 2018

1 reference

Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/AJT.12481

1 reference

9 December 2017

1 reference